Bio-Techne to pay up to $575M for liquid biopsy maker Exosome Diagnostics

Handshake business deal executives
Bio-Techne agreed to pay up to $575 million to acquire liquid biopsy player Exosome Diagnostics, boosting the company’s position in the noninvasive liquid biopsy market. (Pixabay)

Bio-Techne, which makes proteins for biomedical and clinical researchers, will pay up to $575 million to acquire liquid biopsy player Exosome Diagnostics, boosting the company’s position in the noninvasive liquid biopsy market.

Under terms of the transaction, which is expected to be completed by early August, Bio-Techne will shell out $250 million in cash upfront and pay out as much as $325 million as certain milestones are reached, the company said. The deal marks Bio-Techne’s 14th acquisition in the past five years.

“ExosomeDx's technology is a game changer and positions Bio-Techne to be a leader in the rapidly growing noninvasive liquid biopsy market,” Charles Kummeth, Bio-Techne’s president and CEO, said in a statement. “The noninvasive nature of this technology creates a new process for liquid biopsies and is likely to transform medical practice.”

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Exosome launched its Prostate Intelliscore (EPI) test in 2016. It is designed to rule out high-grade prostate cancer in patients, sparing them from an invasive biopsy. Prostate-specific antigen (PSA) screenings return a “relatively high number” of false positives, resulting in men with benign cases of low-grade cancers undergoing uncomfortable biopsies.

With the deal, Bio-Techne is also getting about 200 of Exosome’s filed patents and applications of technology focused on new diagnostics in various pathologies with either difficult or no current diagnostic solutions, such as prostate, bladder, kidney, breast, glioblastoma and other cancers.

Two years ago, Bio-Techne snapped up Advanced Cell Diagnostics in a deal worth up to $325 million for its RNAscope technology, which is an RNA in-situ hybridization platform that allows for the detection of single RNA molecules in single cells.

Suggested Articles

By employing heart rate signals, physical activity and sleep quality, common Fitbit trackers may be able to predict the spread of the flu.

Nanox has raised $26 million to help fuel the development and commercialization of its Star Trek-inspired digital X-ray bed.

Oncology is clearly a major medical and societal issue, but one that sees too much focus from biopharmas at the expense of other killers.